Mergers and Acquisitions in the Global Life Sciences Industry, 2018

Mergers and Acquisitions in the Global Life Sciences Industry, 2018

M&As for Growth in Patient Engagement, Artificial Intelligence and Big Data Analytics are Driving Greater Vertical Integration

RELEASE DATE
07-Mar-2019
REGION
North America
Research Code: MEA4-01-00-00-00
SKU: HC03140-NA-MR_22917
$3,000.00
In stock
SKU
HC03140-NA-MR_22917
$3,000.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Industry report provide details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, contract services diagnostic, and other life science sectors.


Research Highlights

The report provides a detailed understanding and analysis of how and why companies enter M&A deals, which legislative and regulatory policies are promoting M&A activities, and how APAC investors are growing their presence in developed economies, undeterred by policy uncertainties. It also highlights the growing influence of non-traditional players in the life science space and their impact in steering the direction of M&A activity of the traditional players. It further brings out the growing acceptance of digital revenue streams, an under-explored opportunity in connected health. The exponential growth of private equity (PE) investors, and their appetite to invest in high-risk areas, has also allowed unlocking of the potential of several new technologies, creating a ripe environment for corporate acquisitions. At the same time, PE investors’ ability to bid for higher value deals has created competition for the same targets, often outbidding corporate investors.

This study dives deeper into each stakeholder segment to uncover their unique M&A dynamics and chart the activity of top 10 companies in each segment. Several biopharma companies have relied on smaller acquisitions to bolster their R&D pipelines, whereas several others have sought high-value deals to merge or acquire competitor companies in order to achieve critical mass in R&D and ensure continued growth and dominance in the global marketplace. Contract service organizations (CSO) are experiencing the highest rate of consolidation, with the goal of emerging as one-stop-shop solution providers. However, CSOs will soon have to think beyond mere capacity expansion and acquire targets specialized in tangential services like supply chain and patient connectedness. Diagnostic and research tool (DRT) OEMs have experienced a different M&A trend and will have to rely more on value-add services to overcome the slump in M&A derived growth. Strategic imperatives for companies to recalibrate their business models and be future ready are provided in this study as well. Finally, the study also briefly covers growing trends in the outsourcing of innovation, production and selling, and the heightened importance of innovation hubs in promoting M&A.

Key Issues Addressed

  • Which are the emerging power centers as a result of consolidation? Is there a shift in bargaining power?
  • What region-specific factors are prompting M&A? Which regions are experiencing maximum inbound and outbound deals?
  • Is the current rate of M&A sustainable? What will be the rate of shift towards outsourcing?
  • What will be the impact of external disruptors like FAMGA on the direction of acquisitions?
  • Which stakeholders are experiencing the maximum positive and negative impact of M&A?
  • How are mid-sized companies aligning their strategies to survive in this increasingly consolidating space?

Author: Khushbu Jain

Table of Contents

Key Findings

Key Questions this Study will Answer

Big Market Themes

M&A Stakeholder Opportunity Heat Map

Major Growth Opportunities

Strategic Imperatives for the Life Sciences Industry

Scope and Segmentation

Methodology and Assumptions

Methodology and Assumptions (continued)

Regulatory and Legislative Changes Impacting M&A

Non-Traditional Players—Infusing Competition into Traditional Markets

FAMGA* M&A Activity—Comparison with Traditional Healthcare Players

Growing PE Ownership in the Healthcare Space

Growing PE Ownership in the Healthcare Space (continued)

Healthcare M&A Activity

Geographic Distribution of Targets

Market Attractiveness for M&A

Notable M&A Deals

Active Participants in the M&A Landscape

Pharma and Biopharma M&A Activity

Factors Impacting M&A

Roche Case Study—M&A to Create End-to-End Precision Medicine Portfolio

Activity Profile of Top 10 Pharma Companies

Connected Health—From Patient Communication to Engagement

Growth Opportunity 1—Patient Engagement 2.0

Pharmaceutical Companies Can Engage Patients Throughout the Drug Discovery and Development Cycle

Emerging M&A Opportunity Areas

CRO Industry M&A Activity

Eurofins Scientific Case Study—M&A Story of an Emerging Competitor

Activity Profile of Top 10 CRO Companies

Clinical Trial Recruitment and Retention Challenge for CROs

Growth Opportunity 2—Clinical Trial Recruitment and Retention

CDMO Industry M&A Activity

Thermo Fisher and Patheon—Redefining One-stop-shop

Activity Profile of Top 10 CDMO Companies

Will M&A Address the Size Challenge?

Growth Opportunity 3—Cell and Gene Therapy

DRT Industry M&A Activity

Factors Impacting M&A

Invitae Case Study—Genetic Information Company

Activity Profile of Top 10 DRT Companies

A Very Active PE Landscape—Increasing Valuations

Rising Valuations—A New Challenge for M&A

Growth Opportunity 4—Insight-as-a-Service

Concluding Thoughts

Top 3 Predictions

Legal Disclaimer

M&A and Collaboration Drivers

Top Technologies Attracting PE Investment

Collaboration Assessment

Collaboration Assessment (continued)

Collaboration Assessment (continued)

Collaboration Assessment (continued)

Collaboration Assessment (continued)

List of Exhibits

List of Exhibits (continued)

The Frost & Sullivan Story

Value Proposition—Future of Your Company & Career

Global Perspective

Industry Convergence

360º Research Perspective

Implementation Excellence

Our Blue Ocean Strategy

Related Research
The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Industry report provide details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, contract services diagnostic, and other life science sectors.--BEGIN PROMO--

Research Highlights

The report provides a detailed understanding and analysis of how and why companies enter M&A deals, which legislative and regulatory policies are promoting M&A activities, and how APAC investors are growing their presence in developed economies, undeterred by policy uncertainties. It also highlights the growing influence of non-traditional players in the life science space and their impact in steering the direction of M&A activity of the traditional players. It further brings out the growing acceptance of digital revenue streams, an under-explored opportunity in connected health. The exponential growth of private equity (PE) investors, and their appetite to invest in high-risk areas, has also allowed unlocking of the potential of several new technologies, creating a ripe environment for corporate acquisitions. At the same time, PE investors’ ability to bid for higher value deals has created competition for the same targets, often outbidding corporate investors.

This study dives deeper into each stakeholder segment to uncover their unique M&A dynamics and chart the activity of top 10 companies in each segment. Several biopharma companies have relied on smaller acquisitions to bolster their R&D pipelines, whereas several others have sought high-value deals to merge or acquire competitor companies in order to achieve critical mass in R&D a

More Information
No Index No
Podcast No
Author Khushbu Jain
Industries Healthcare
WIP Number MEA4-01-00-00-00
Is Prebook No
GPS Codes 9564-B1,9575-B1,9600-B1,9612-B1,9A56-B1,9562-B1,9571-B1,9573-B1,99BC-B1,99C1-B1,99C6-B1,9568-B1,9611-B1,9627-B1